The Elucid platform is an FDA-Cleared and CE-Marked software to objectively quantify plaque morphology validated against tissue specimens. Specifically, the exquisite algorithms developed through machine learning characterize tissue types in the artery wall known to cause heart attacks, such as lipid rich necrotic core.
The round was led by an undisclosed strategic investor, with participation from Biovision Ventures, a new Europe-based fund, and existing investors, including MedTex Ventures, IAG Capital, Bold Brain Ventures, and BlueStone Venture Partners.
The capability to discern complex plaque biology at the cellular and molecular level is powering new applications that can derive fractional flow reserve (FFRct), risk of heart attack/stroke, and expression prediction to inform therapeutic selection. This comprehensive approach enables physicians to diagnose not only the direct cause of chest pain but also to determine if patients have early-stage heart disease which cannot be seen by alternative methods. Elucid unlocks the power to personalize clinical pathways and prevent the debilitating effects of atherosclerosis before they begin.
“Elucid is committed to providing physicians the most rigorously validated diagnostic platform to fight cardiovascular disease. Every patient is different and needs to be treated specific to his or her individual disease,” says Blake Richards, CEO of Elucid. “We are so proud of the remarkable work our team has accomplished and this Series B allows us to expand our commercial reach. We warmly welcome our new investors and are grateful to our existing investors for their continued support in achieving our mission.”
John Fichthorn of MedTex Ventures added: “Elucid’s basis in histopathology is highly differentiated from competitive methods and is paramount to understanding the key drivers of atherosclerosis which cause ischemia and heart attacks. This company’s approach, technology, and team will finally stop heart disease in its tracks.”